Does Rallies show 13F holders for CTNM?

Yes. Rallies tracks hedge fund and 13F ownership data for CTNM, including fund names, share counts, latest tracked quarter, and position changes when available.

Is CTNM research on Rallies investment advice?

No. Rallies provides research, data, and educational context for CTNM. It does not provide personalized investment advice.

CTNM (Contineum Therapeutics, Inc. Class A Common Stock) Stock Analysis - Hedge Fund Holdings

Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is a publicly traded Healthcare sector company. As of May 21, 2026, CTNM trades at $13.40 with a market cap of $480.79M and a P/E ratio of -6.13. CTNM moved +5.72% today. Year to date, CTNM is +33.90%; over the trailing twelve months it is +249.61%. Its 52-week range spans $3.35 to $20.24. Analyst consensus is strong buy with an average price target of $21.00. Rallies surfaces CTNM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns CTNM stock?

Hedge funds tracked by Rallies that own CTNM include Exoduspoint Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Contineum Therapeutics, Inc. Class A Common Stock.

CTNM Key Metrics

Key financial metrics for CTNM
Metric	Value
Price	$13.40
Market Cap	$480.79M
P/E Ratio	-6.13
EPS	$-2.17
Dividend Yield	0.00%
52-Week High	$20.24
52-Week Low	$3.35
Volume	1
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-59.98M
Gross Margin	0.00%

Top Hedge Funds Holding CTNM

Exoduspoint Capital holds 12.38K shares of CTNM, changed -75.73% as of Mar 31, 2026.

Latest CTNM News

Analysts See 91.5% Upside for Contineum Therapeutics After Zacks Rank #2 Upgrade — Dec 31, 2025

Recent CTNM Insider Trades

Lorrain Daniel S. sold 3.87K (~$50.54K) on May 1, 2026.
Lorrain Daniel S. sold 300 (~$4.15K) on May 1, 2026.
Lorrain Daniel S. sold 4.17K (~$56.01K) on Apr 6, 2026.

CTNM Analyst Consensus

6 analysts cover CTNM: 0 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $21.00.

Common questions about CTNM

Who owns CTNM stock?: Hedge funds tracked by Rallies that own CTNM include Exoduspoint Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Contineum Therapeutics, Inc. Class A Common Stock.
Does Rallies show 13F holders for CTNM?: Yes. Rallies tracks hedge fund and 13F ownership data for CTNM, including fund names, share counts, latest tracked quarter, and position changes when available.
Is CTNM research on Rallies investment advice?: No. Rallies provides research, data, and educational context for CTNM. It does not provide personalized investment advice.